SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-05245

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
MGGL	NICARAGUA	02	Dec	2016	8	Female			2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Light vaginal bleeding (Vaginal bleeding (10046883), Vaginal haemorrhage (10046910))
(//2025 - /May/2025) - Recovered/Resolved
2) Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty (Off label use (10053762), Off label use (10053762))
(29/Apr/2025 -) - Not Recovered/Not Resolved/Ongoing

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
1) (22.5 milligram(s), 1 in 3 Month)	1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
(29-Apr-2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-05245
24c. DATE RECEIVED BY MANUFACTURER: 29/Jul/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 05/Aug/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via Patient Support Programme (Reference number: NI-ADIUM-NI-0061-20250729 (0)) on 29-Jul-2025 from a consumer (non-healthcare professional) regarding a child, 08-year-old female patient who experienced non-serious events of ''Light vaginal bleeding" (Vaginal haemorrhage) and "Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty" (off label use) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 30-Jul-2025.

The patient's medical history was unknown and current condition included precocious puberty.

Concomitant medication was unknown.

On 29-Apr-2025, the patient began receiving Eligard 22.5 mg every 3 months, via subcutaneous route, for precocious puberty (Lot numbers and Expiration dates were not provided).

On an unknown date in 2025, the patient experienced scanty vaginal bleeding. No further details were provided.

Corrective treatment was unknown.

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

On an unknown date in May-2025, the outcome of vaginal haemorrhage was resolved.

The outcome of off label use was not recovered.

The reporter did not assess the seriousness of vaginal haemorrhage and off label use.

The reporter did not provide the causality of off label use in relationship to Eligard and Eligard unspecified device.

The reporter assessed the causality of vaginal haemorrhage in relationship to Eligard and Eligard unspecified device as related.

No further query was raised.

Listedness:
Vaginal haemorrhage>Eligard>listed as per CCDS>07-Nov-2024
Vaginal haemorrhage>Eligard>Unlisted as per USPI>Feb-2025
Vaginal haemorrhage>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Vaginal haemorrhage>Eligard>listed as per Canadian monograph>02-Apr-2025

Off label use>Eligard>Unlisted as per CCDS>07-Nov-2024
Off label use>Eligard>Unlisted as per USPI>Feb-2025
Off label use>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Off label use>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This case is regarding a female patient 08-year-old (child) for whom off label use (Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty) and experienced vaginal haemorrhage (Light vaginal bleeding) was reported during 22.5 mg Eligard therapy for precocious puberty. Tolmar assessed the events as non-serious since they did not meet the ICH seriousness criteria and are not an IME events. The reported event off label use was considered as not related to Eligard as the event occurred with the product and not due to drug. Off label use is assessed as not related to device component of Eligard. The event vaginal haemorrhage was assessed as related to Eligard (Drug), considering known pharmacological profile of the drug and pubertal age group of the patient could be the confounding factor. Event vaginal haemorrhage was assessed as not related to device component of Eligard.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form of Admin	: 1) Injection
Lot Number	: 1) Unknown
Daily Dose	: (22.5 milligram(s), 1 in 3 Month)

Continuation Sheet for CIOMS report

Route of Admin : 1) Subcutaneous
Indications : 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug : Dose not changed

Causality

1) Light vaginal bleeding (Vaginal bleeding - 10046883, Vaginal haemorrhage - 10046910)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty (Off label use - 10053762, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Light vaginal bleeding
CORE Labeled

2) Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug : Not applicable

Causality

1) Light vaginal bleeding (Vaginal bleeding - 10046883, Vaginal haemorrhage - 10046910)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty (Off label use - 10053762, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Light vaginal bleeding
CORE

2) Eligard 22.5 mg lyophilized for injectable suspension at a dose of 22.5 mg every 3 months for the indication of Central Precocious Puberty
CORE